Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.08 USD | +2.33% | -2.84% | -20.62% |
Apr. 18 | Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board | CI |
Mar. 12 | Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 96.02M |
---|---|---|---|---|---|
Net income 2024 * | -14M | Net income 2025 * | -15M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.84
x | P/E ratio 2025 * |
-6.69
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.1% |
Latest transcript on Anixa Biosciences, Inc.
1 day | +2.33% | ||
1 week | -2.84% | ||
Current month | -1.28% | ||
1 month | -4.64% | ||
3 months | -37.14% | ||
6 months | -4.94% | ||
Current year | -20.62% |
Managers | Title | Age | Since |
---|---|---|---|
Amit Kumar
CEO | Chief Executive Officer | 59 | 12-10-31 |
Michael Catelani
DFI | Director of Finance/CFO | 57 | 16-10-31 |
Pamela Garzone
PRN | Corporate Officer/Principal | 69 | 21-09-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lewis Titterton
BRD | Director/Board Member | 79 | 99-06-30 |
Amit Kumar
CEO | Chief Executive Officer | 59 | 12-10-31 |
Emily Gottschalk
BRD | Director/Board Member | 63 | 19-10-22 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 3.01 | -3.53% | 57,975 |
24-04-19 | 3.12 | +0.65% | 32,692 |
24-04-18 | 3.1 | +1.64% | 58,503 |
24-04-17 | 3.05 | -3.79% | 72,904 |
24-04-16 | 3.17 | +0.32% | 78,207 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.62% | 96.02M | |
+3.13% | 42.11B | |
+48.83% | 40.08B | |
+8.49% | 40B | |
-10.82% | 26.87B | |
+8.26% | 24.58B | |
-23.69% | 18.44B | |
+1.58% | 11.94B | |
+32.83% | 11.66B | |
+6.63% | 11.01B |
- Stock Market
- Equities
- ANIX Stock